| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037635435 |
| P356 | DOI | 10.1186/S12890-016-0339-5 |
| P932 | PMC publication ID | 5139081 |
| P698 | PubMed publication ID | 27919253 |
| P50 | author | Anjali Y Bhagirath | Q88231318 |
| Kangmin Duan | Q38803382 | ||
| P2093 | author name string | Yanqi Li | |
| Sara Badr | |||
| Maryam Dadashi | |||
| Deepti Somayajula | |||
| P2860 | cites work | Diverse virulent pneumophages infect Streptococcus mitis | Q21090561 |
| Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients | Q21562196 | ||
| Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone | Q24312937 | ||
| Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients | Q24551181 | ||
| Micro- and macrorheology of mucus | Q24643968 | ||
| CFTR regulation of epithelial sodium channel | Q48674138 | ||
| The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel | Q48890761 | ||
| Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. | Q50490592 | ||
| Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model | Q35914177 | ||
| Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections | Q35918209 | ||
| Insights into the respiratory tract microbiota of patients with cystic fibrosis during early Pseudomonas aeruginosa colonization | Q35930737 | ||
| Adolescents' Spirituality and Cystic Fibrosis Airway Clearance Treatment Adherence: Examining Mediators | Q35977448 | ||
| Culture-Independent Identification of Nontuberculous Mycobacteria in Cystic Fibrosis Respiratory Samples | Q35993825 | ||
| Identification of genes in the σ²² regulon of Pseudomonas aeruginosa required for cell envelope homeostasis in either the planktonic or the sessile mode of growth | Q36025901 | ||
| Tackling the increasing complexity of CF care | Q36034488 | ||
| Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung | Q36079160 | ||
| Submucosal glands and airway defense | Q36236757 | ||
| A reconstruction of the duct system and secretory tubules of the human bronchial submucosal gland | Q36484828 | ||
| Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function | Q36491305 | ||
| Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment | Q36559330 | ||
| Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. | Q36609344 | ||
| Acidic pH increases airway surface liquid viscosity in cystic fibrosis | Q36618542 | ||
| Cystic fibrosis: a mucosal immunodeficiency syndrome. | Q36623329 | ||
| Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study | Q36677316 | ||
| Increased susceptibility of Cftr-/- mice to LPS-induced lung remodeling | Q36811246 | ||
| Airway acidification initiates host defense abnormalities in cystic fibrosis mice. | Q36857687 | ||
| Cystic fibrosis: a polymicrobial infectious disease | Q36895733 | ||
| Iron in infection and immunity | Q36913895 | ||
| Lessons learned from the cystic fibrosis pig. | Q36948394 | ||
| Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers | Q36980425 | ||
| Cigarette smoke inhibition of ion transport in canine tracheal epithelium | Q36989691 | ||
| New developments in the epidemiology and clinical spectrum of rhinovirus infections | Q37057738 | ||
| Cystic fibrosis: a model system for precision medicine. | Q37097931 | ||
| Cooperative assembly and misfolding of CFTR domains in vivo. | Q37146655 | ||
| Altered Th17/Treg Ratio in Nasal Polyps With Distinct Cytokine Profile: Association With Patterns of Inflammation and Mucosal Remodeling | Q37207077 | ||
| Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa | Q37223605 | ||
| Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis | Q37304358 | ||
| Long-Term Rasamsonia argillacea Complex Species Colonization Revealed by PCR Amplification of Repetitive DNA Sequences in Cystic Fibrosis Patients | Q37363443 | ||
| The type III secretion system of Pseudomonas aeruginosa: infection by injection | Q37397923 | ||
| Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene | Q37418902 | ||
| Gating of the CFTR Cl- channel by ATP-driven nucleotide-binding domain dimerisation | Q37427078 | ||
| Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation. | Q37428607 | ||
| Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 | Q24644303 | ||
| The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases | Q24655891 | ||
| Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease | Q26741691 | ||
| Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis | Q26765794 | ||
| Genome-editing Technologies for Gene and Cell Therapy | Q26769662 | ||
| Innate immunity in cystic fibrosis lung disease | Q27003347 | ||
| Structural Insights into the Effector – Immunity System Tse1/Tsi1 from Pseudomonas aeruginosa | Q27670727 | ||
| Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences | Q27676826 | ||
| The Impact of Secondhand Smoke Exposure on Children with Cystic Fibrosis: A Review | Q28076884 | ||
| Generating human intestinal tissues from pluripotent stem cells to study development and disease | Q28081264 | ||
| Airway Gland Structure and Function | Q28082284 | ||
| Cell delivery of therapeutic nanoparticles | Q28385606 | ||
| A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria | Q28492922 | ||
| A new regulator of pathogenicity (bvlR) is required for full virulence and tight microcolony formation in Pseudomonas aeruginosa | Q28493167 | ||
| Type VI secretion delivers bacteriolytic effectors to target cells | Q28493220 | ||
| Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cftr ΔF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery | Q28508259 | ||
| Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis | Q28551306 | ||
| The cystic fibrosis lower airways microbial metagenome | Q28596642 | ||
| The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management | Q28730299 | ||
| A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa | Q29615302 | ||
| The inflammasome NLRs in immunity, inflammation, and associated diseases | Q29616025 | ||
| Structure of a bacterial multidrug ABC transporter | Q29617308 | ||
| Persister cells | Q30018300 | ||
| Cystic fibrosis. | Q30251439 | ||
| Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens | Q30599406 | ||
| Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. | Q31030261 | ||
| Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa | Q33281164 | ||
| Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections | Q33379091 | ||
| Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals | Q33509530 | ||
| IFN-γ stimulates autophagy-mediated clearance of Burkholderia cenocepacia in human cystic fibrosis macrophages | Q33568014 | ||
| Iron acquisition and metabolism by mycobacteria | Q33635173 | ||
| Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation | Q33654992 | ||
| Strict coupling between CFTR's catalytic cycle and gating of its Cl- ion pore revealed by distributions of open channel burst durations. | Q33666969 | ||
| Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome | Q33733606 | ||
| Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. | Q35124468 | ||
| Emerging cystic fibrosis pathogens and the microbiome | Q35169553 | ||
| Pseudomonas aeruginosa-induced bleb-niche formation in epithelial cells is independent of actinomyosin contraction and enhanced by loss of cystic fibrosis transmembrane-conductance regulator osmoregulatory function | Q35172336 | ||
| Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals | Q35172371 | ||
| Pharmacological correction of misfolding of ABC proteins | Q35207294 | ||
| The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation | Q35237897 | ||
| Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. | Q35350270 | ||
| Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis | Q35533349 | ||
| Associations between Gut Microbial Colonization in Early Life and Respiratory Outcomes in Cystic Fibrosis | Q35589259 | ||
| The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis. | Q35591092 | ||
| Liquid secretion properties of airway submucosal glands | Q35602056 | ||
| Lung microbiota across age and disease stage in cystic fibrosis | Q35605802 | ||
| The bacterial microbiota in inflammatory lung diseases | Q35677622 | ||
| Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease | Q35690337 | ||
| Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing. | Q35749642 | ||
| Staphylococcus aureus Inhibits IL-8 Responses Induced by Pseudomonas aeruginosa in Airway Epithelial Cells. | Q35770809 | ||
| Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium | Q35781735 | ||
| Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention | Q35837327 | ||
| Clinical Insights into Pulmonary Exacerbations in Cystic Fibrosis from the Microbiome. What Are We Missing? | Q35848712 | ||
| Microbiota manipulation for weight change | Q35899713 | ||
| Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis | Q35913962 | ||
| Regulation of ENaC and CFTR expression with K+ channel modulators and effect on fluid absorption across alveolar epithelial cells | Q42499314 | ||
| Mucus secretion from single submucosal glands of pig. Stimulation by carbachol and vasoactive intestinal peptide | Q42521391 | ||
| CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains | Q42575484 | ||
| Molecular models of the open and closed states of the whole human CFTR protein | Q42631749 | ||
| New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation. | Q42656147 | ||
| CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship | Q42809539 | ||
| Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis | Q43257270 | ||
| Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization | Q43745856 | ||
| Airway surface pH in subjects with cystic fibrosis | Q44304465 | ||
| Synergistic effects of cystic fibrosis transmembrane conductance regulator and aquaporin-9 in the rat epididymis | Q44328930 | ||
| The cystic fibrosis airway microbiome | Q44696026 | ||
| Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in the Danish Cystic Fibrosis Centre | Q45238841 | ||
| Self-esteem and its relationship to mental health and quality of life in adults with cystic fibrosis. | Q45955644 | ||
| Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis | Q46453243 | ||
| Wealth as a disease modifier in cystic fibrosis | Q46487862 | ||
| Ivacaftor in a G551D homozygote with cystic fibrosis | Q46798445 | ||
| Mucus clearance and lung function in cystic fibrosis with hypertonic saline | Q46900192 | ||
| Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure | Q46923807 | ||
| Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis | Q46931583 | ||
| Health Related Quality of Life of Children with Chronic Respiratory Conditions | Q47632081 | ||
| Structural airway abnormalities in infants and young children with cystic fibrosis | Q48024125 | ||
| Cystic Fibrosis Transmembrane Conductance Regulator Function in Airway Smooth Muscle. A Novel Role in Cystic Fibrosis Airway Obstruction. | Q48239970 | ||
| Non-specific activation of the epithelial sodium channel by the CFTR chloride channel | Q33757239 | ||
| Neonates with cystic fibrosis have a reduced nasal liquid pH; a small pilot study | Q33766585 | ||
| Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections | Q33786154 | ||
| Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. | Q33815570 | ||
| Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. | Q33859051 | ||
| The airway microbiome in cystic fibrosis and implications for treatment | Q33873287 | ||
| Nutrition and lung function in cystic fibrosis patients: review | Q33950680 | ||
| Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France. | Q34030917 | ||
| Ultrastructure of cells in the human bronchial submucosal glands | Q34042023 | ||
| A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy | Q34047949 | ||
| Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function | Q34168616 | ||
| CFTR and calcium-activated chloride channels in primary cultures of human airway gland cells of serous or mucous phenotype | Q34212692 | ||
| Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes | Q34248249 | ||
| Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience | Q34307354 | ||
| Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study | Q34333563 | ||
| Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children | Q34402437 | ||
| Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities | Q34404215 | ||
| Recent advances in the management of cystic fibrosis | Q34427981 | ||
| The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations | Q34437958 | ||
| Iron Depletion Enhances Production of Antimicrobials by Pseudomonas aeruginosa | Q34473890 | ||
| Clinical significance of microbial infection and adaptation in cystic fibrosis | Q34491552 | ||
| Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis | Q34536205 | ||
| Recent developments in targeting protein misfolding diseases | Q34604968 | ||
| Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. | Q34661901 | ||
| Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation | Q34665000 | ||
| Molecular mechanisms of calcium-sensing receptor-mediated calcium signaling in the modulation of epithelial ion transport and bicarbonate secretion | Q34683229 | ||
| Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. | Q34743353 | ||
| The microbial community of the cystic fibrosis airway is disrupted in early life | Q34744222 | ||
| PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model | Q34749864 | ||
| Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis--a review | Q34910464 | ||
| Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis. | Q34974098 | ||
| Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SS | Q35019815 | ||
| Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis | Q35023645 | ||
| Application of a neutral community model to assess structuring of the human lung microbiome | Q35072309 | ||
| Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. | Q50674363 | ||
| Marker genes for the metabolic adaptation of Pseudomonas aeruginosa to the hypoxic cystic fibrosis lung environment. | Q51703439 | ||
| Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. | Q51711090 | ||
| Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. | Q51729130 | ||
| Inactivation of MuxABC-OpmB transporter system in Pseudomonas aeruginosa leads to increased ampicillin and carbenicillin resistance and decreased virulence. | Q52716510 | ||
| Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. | Q53297625 | ||
| Persister cells: molecular mechanisms related to antibiotic tolerance. | Q54325081 | ||
| Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. | Q54373452 | ||
| Bronchial measurement with three-dimensional quantitative thin-section CT in patients with cystic fibrosis | Q56786450 | ||
| Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis | Q57913654 | ||
| Hybrid sensor kinase PA1611 inPseudomonas aeruginosaregulates transitions between acute and chronic infection through direct interaction with RetS | Q59297522 | ||
| Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition | Q61963445 | ||
| Gene therapy for cystic fibrosis | Q64376611 | ||
| Submucosal glands are the predominant site of CFTR expression in the human bronchus | Q67469589 | ||
| Viral infection in cystic fibrosis | Q68884967 | ||
| Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years | Q70736159 | ||
| CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands | Q73071091 | ||
| Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening | Q73107610 | ||
| The spectrum of mycobacterial infection after lung transplantation | Q73168479 | ||
| Effect of anion transport inhibition on mucus secretion by airway submucosal glands | Q73281477 | ||
| Acetylcholine-induced liquid secretion by bronchial epithelium: role of Cl- and HCO3- transport | Q77649774 | ||
| Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-kappaB expression | Q77855663 | ||
| Clara cell protein-positive epithelial cells are reduced in small airways of asthmatics | Q78203144 | ||
| The role of respiratory viruses in cystic fibrosis | Q80647522 | ||
| High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial | Q80844719 | ||
| Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions | Q81025238 | ||
| Fungal respiratory infections in cystic fibrosis: a growing problem | Q82411001 | ||
| McKay agar enables routine quantification of the 'Streptococcus milleri' group in cystic fibrosis patients | Q82606971 | ||
| Influence of DNA on the activities and inhibition of neutrophil serine proteases in cystic fibrosis sputum | Q83462729 | ||
| Managing treatment complexity in cystic fibrosis: challenges and opportunities | Q83786915 | ||
| Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis | Q84219534 | ||
| CD4(+)CD25(high) FOXP3(+) regulatory T cells correlate with FEV1 in North Indian children with cystic fibrosis | Q87503963 | ||
| Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage in cystic fibrosis | Q87637126 | ||
| Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis | Q88181025 | ||
| Immunocytochemical localization of the cystic fibrosis gene product CFTR | Q37609030 | ||
| Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy | Q37788421 | ||
| Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance | Q37794342 | ||
| The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture | Q37843465 | ||
| Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. | Q37860758 | ||
| The serous cell | Q37876724 | ||
| Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung | Q37981915 | ||
| Exercise as part of a cystic fibrosis therapeutic routine | Q38025731 | ||
| Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis | Q38042346 | ||
| Recognition of bacteria by inflammasomes | Q38065190 | ||
| Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health | Q38094297 | ||
| Fungal infections and treatment in cystic fibrosis | Q38141603 | ||
| The role of neutrophils in cystic fibrosis | Q38164217 | ||
| Current concepts of immune dysregulation in cystic fibrosis. | Q38185216 | ||
| Detrimental effects of secondhand smoke exposure on infants with cystic fibrosis | Q38194542 | ||
| Architecture and assembly of the Type VI secretion system. | Q38200408 | ||
| The problems of antibiotic resistance in cystic fibrosis and solutions | Q38300820 | ||
| Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial | Q38373785 | ||
| CFTR, bicarbonate, and the pathophysiology of cystic fibrosis | Q38579954 | ||
| Update on host-pathogen interactions in cystic fibrosis lung disease | Q38605085 | ||
| Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening. | Q38962286 | ||
| Purinergic regulation of CFTR and Ca(2+)-activated Cl(-) channels and K(+) channels in human pancreatic duct epithelium | Q39201947 | ||
| Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis | Q39455047 | ||
| Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center | Q39514745 | ||
| Effect of residential proximity to major roadways on cystic fibrosis exacerbations | Q39578759 | ||
| Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections | Q39656697 | ||
| Treatment burden in patients with at least one class IV or V CFTR mutation | Q40352553 | ||
| Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates | Q40421266 | ||
| Early infection and progression of cystic fibrosis lung disease | Q40636854 | ||
| Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate | Q40841860 | ||
| Abnormal glutathione transport in cystic fibrosis airway epithelia | Q40941623 | ||
| Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. | Q40968095 | ||
| Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark | Q41145157 | ||
| Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis | Q41148531 | ||
| Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 | Q41148574 | ||
| Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells | Q41404505 | ||
| Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic | Q41448149 | ||
| Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis | Q41541158 | ||
| Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. | Q41712968 | ||
| CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney | Q42018121 | ||
| Naturally produced outer membrane vesicles from Pseudomonas aeruginosa elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components | Q42181392 | ||
| Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function | Q42321930 | ||
| Bile acids stimulate chloride secretion through CFTR and calcium-activated Cl- channels in Calu-3 airway epithelial cells | Q42461659 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | respiratory system | Q7891 |
| perinatal disease | Q18968218 | ||
| cystic fibrosis | Q178194 | ||
| Pseudomonas aeruginosa | Q31856 | ||
| host microbial interaction | Q68260314 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 174 | |
| P577 | publication date | 2016-12-05 | |
| P1433 | published in | BMC Pulmonary Medicine | Q15755469 |
| P1476 | title | Cystic fibrosis lung environment and Pseudomonas aeruginosa infection | |
| P478 | volume | 16 |
| Q62672846 | A Gcn5-Related N-Acetyltransferase (GNAT) Capable of Acetylating Polymyxin B and Colistin Antibiotics in Vitro |
| Q57041845 | Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms |
| Q64077063 | Anaerobiosis influences virulence properties of Pseudomonas aeruginosa cystic fibrosis isolates and the interaction with Staphylococcus aureus |
| Q89860564 | Anti-Infectives Restore ORKAMBI® Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa |
| Q50141927 | Association of Nutritional Status with Lung Function and Morbidity in Children and Adolescents with Cystic Fibrosis: A 36-Month Cohort Study |
| Q91801396 | Biofilms: Novel Strategies Based on Antimicrobial Peptides |
| Q91934202 | Bronchial epithelium repair by Esculentin-1a-derived antimicrobial peptides: involvement of metalloproteinase-9 and interleukin-8, and evaluation of peptides' immunogenicity |
| Q57477855 | Chronic Infections: A Possible Scenario for Autophagy and Senescence Cross-Talk |
| Q47612389 | CmpX Affects Virulence in Pseudomonas aeruginosa Through the Gac/Rsm Signaling Pathway and by Modulating c-di-GMP Levels. |
| Q33809988 | D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection |
| Q98215924 | Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa |
| Q47135274 | Environmental Burkholderia cenocepacia Strain Enhances Fitness by Serial Passages during Long-Term Chronic Airways Infection in Mice |
| Q90230125 | Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling |
| Q99712064 | Fostering Innovation in the Treatment of Chronic Polymicrobial Cystic Fibrosis-Associated Infections Exploring Aspartic Acid and Succinic Acid as Ciprofloxacin Adjuvants |
| Q57170365 | From General to Specific: Can Pseudomonas Primary Metabolism Be Exploited for Narrow-Spectrum Antibiotics? |
| Q56891272 | High-resolution in situ transcriptomics of Pseudomonas aeruginosa unveils genotype independent patho-phenotypes in cystic fibrosis lungs |
| Q55233739 | Hypertonic Saline Suppresses NADPH Oxidase-Dependent Neutrophil Extracellular Trap Formation and Promotes Apoptosis. |
| Q95840967 | ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure |
| Q93162740 | In vitro evolution of Pseudomonas aeruginosa AA2 biofilms in the presence of cystic fibrosis lung microbiome members |
| Q93010095 | Interactions between the gut microbiome and host gene regulation in cystic fibrosis |
| Q92603681 | Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy |
| Q99413489 | Lung immunoglobulin A immunity dysregulation in cystic fibrosis |
| Q52448914 | Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection. |
| Q90326796 | Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients |
| Q89579396 | Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations |
| Q92238970 | Mutagenesis Induced by Sub-Lethal Doses of Ciprofloxacin: Genotypic and Phenotypic Differences Between the Pseudomonas aeruginosa Strain PA14 and Clinical Isolates |
| Q92542722 | Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis |
| Q50044377 | Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model. |
| Q90161335 | PTP1B negatively regulates nitric oxide-mediated Pseudomonas aeruginosa killing by neutrophils |
| Q92823732 | Peptide-Based Efflux Pump Inhibitors of the Small Multidrug Resistance Protein from Pseudomonas aeruginosa |
| Q57490973 | Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer |
| Q64101109 | Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation |
| Q47640423 | Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections |
| Q92328624 | Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections |
| Q90261920 | Repurposing bioactive compounds for treating multidrug-resistant pathogens |
| Q52569918 | Standard (head-down tilt) versus modified (without head-down tilt) postural drainage in infants and young children with cystic fibrosis. |
| Q90330715 | Stuffed Methyltransferase Catalyzes the Penultimate Step of Pyochelin Biosynthesis |
| Q92707838 | Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model |
| Q92071604 | Synergy Pattern of Short Cationic Antimicrobial Peptides Against Multidrug-Resistant Pseudomonas aeruginosa |
| Q41660396 | The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum. |
| Q40119729 | Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates |
Search more.